Immunotherapy and chemo before and after surgery for skull base cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of immunotherapy and chemotherapy given before surgery, followed by immunotherapy alone after surgery, for a type of head and neck cancer that has spread to the skull base. The goal is to see if this approach can help shrink the tumor and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 80 years old
- Diagnosed with squamous cell carcinoma in the mouth, throat, or sinus that has spread to the skull base
- Have not had any previous treatment for this cancer (chemotherapy, radiation, or immunotherapy)
- Able to have surgery and chemotherapy, with good overall health (ECOG score 0 or 1)
- No autoimmune diseases requiring long-term steroid or immune-suppressing drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests combining immunotherapy (camrelizumab) with standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
Hear when a new Head and Neck Cancer Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.